Efficacy of Intravitreal Bevacizumab in Vitreous Hemorrhage

Abstract

Shruthi Kavinamoole

Aim To evaluate the efficacy of intravitreal bevacizumab in improving visual outcome and preventing the recurrence in vitreous hemorrhage.

Setting Manjunatha eye hospital, Kundapura, Udupi.

Design Clinical prospective study

Materials and Methods 30 eyes of 30 patients were included in this study. 12 were females and 18 were males. All the patients underwent initial ophthalmological examination with visual acuity, refraction, anterior segment examination, intraocular pressure and dilated fundoscopy. All the patients where given intravitreal injection bevacizumab 1.25mg/0.05ml on monthly basis. Patients were followed up 1week post injection and visual acuity, anterior segment evaluation, IOP, posterior segment examination were done.

Statistical Analysis Data was analyzed using descriptive statistics.

Results 30 eyes of 30 patients were included in this study. 12 were females and 18 were males. BCVA in all the 30 patients were less than counting fingers at half meters. Following 1st month, 13 patients had a BCVA better than 6/60. Remaining 17 patients had less than 6/60BCVA. By the end of 3months, 3patients had BCVA less than 6/60, 15patients had BCVA of 6/24-6/60, 8patients had BCVA between -6/246/9 and 4patients had 6/6vision. By the end of 6months, 11patients had BCVA6/60-6/24, 1patient had 6/24-6/9BCVA and 3patients had BCVA of 6/9 and 5patients had 6/6vision.

Conclusion Intravitreal bevacizumab is an effective way in improving visual outcome and in preventing the recurrence in vitreous hemorrhage. It also efficiently avoids the need of surgical intervention in any type of vitreous hemorrhage.

PDF